Form 4: Vertex Pharmaceuticals Director Acquires Deferred Stock Units

Bruce I. Sachs, a director of Vertex Pharmaceuticals, acquired deferred stock units representing 111.654 shares of common stock on January 15, 2025.

Summary

• On January 15, 2025, Bruce I. Sachs, a director at Vertex Pharmaceuticals, acquired 111.654 deferred stock units.
• Each deferred stock unit represents one share of Vertex Pharmaceuticals common stock.
• The price of each deferred stock unit was $420.31.
• These units will be paid out in common stock upon the earliest occurrence of Mr. Sachs' service termination on the board, a change of control of the company, or Mr. Sachs' disability or death.
• Following the transaction, Mr. Sachs beneficially owns 15,144.986 shares of common stock.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing regarding stock ownership. It doesn't inherently convey positive or negative sentiment.

Future Outlook

The deferred stock units will be paid out in common stock upon the earliest to occur of (i) termination of Mr. Sachs' service on our board of directors, (ii) a change of control of our company and (iii) Mr. Sachs' disability or death.

Industry Context

This Form 4 filing is a routine disclosure of a director's acquisition of deferred stock units, which is a common form of executive compensation in publicly traded companies. It reflects ongoing alignment of director interests with shareholder value.

Stakeholder Impact

• The acquisition of deferred stock units by a director aligns their interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates